The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
New home-use glucometer delivers results in under 10 seconds with simplified testing, large memory storage, and user-friendly design
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
The submission is backed by positive results from the Phase 3 AFFIRM study
Subscribe To Our Newsletter & Stay Updated
